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Abstract
Background: Despite the widespread use of interferon-c release assays (IGRAs), their role in diagnosing tuberculosis and
targeting preventive therapy in HIV-infected patients remains unclear. We conducted a comprehensive systematic review to
contribute to the evidence-based practice in HIV-infected people.
Methodology/Principal Findings: We searched MEDLINE, Cochrane, and Biomedicine databases to identify articles
published between January 2005 and July 2011 that assessed QuantiFERONH-TB Gold In-Tube (QFT-GIT) and T-SPOTH.TB (T-
SPOT.TB) in HIV-infected adults. We assessed their accuracy for the diagnosis of tuberculosis and incident active
tuberculosis, and the proportion of indeterminate results. The search identified 38 evaluable studies covering a total of 6514
HIV-infected participants. The pooled sensitivity and specificity for tuberculosis were 61% and 72% for QFT-GIT, and 65%
and 70% for T-SPOT.TB. The cumulative incidence of subsequent active tuberculosis was 8.3% for QFT-GIT and 10% for T-
SPOT.TB in patients tested positive (one study each), and 0% for QFT-GIT (two studies) and T-SPOT.TB (one study)
respectively in those tested negative. Pooled indeterminate rates were 8.2% for QFT-GIT and 5.9% for T-SPOT.TB. Rates were
higher in high burden settings (12.0% for QFT-GIT and 7.7% for T-SPOT.TB) than in low-intermediate burden settings (3.9%
for QFT-GIT and 4.3% for T-SPOT.TB). They were also higher in patients with CD4
+ T-cell count ,200 (11.6% for QFT-GIT and
11.4% for T-SPOT.TB) than in those with CD4
+ T-cell count $200 (3.1% for QFT-GIT and 7.9% for T-SPOT.TB).
Conclusions/Significance: IGRAs have suboptimal accuracy for confirming or ruling out active tuberculosis disease in HIV-
infected adults. While their predictive value for incident active tuberculosis is modest, a negative QFT-GIT implies a very low
short- to medium-term risk. Identifying the factors associated with indeterminate results will help to optimize the use of
IGRAs in clinical practice, particularly in resource-limited countries with a high prevalence of HIV-coinfection.
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Introduction
Tuberculosis is one of the leading causes of mortality in people
living with human immunodeficiency virus (HIV) worldwide,
particularly in sub-Saharan Africa, where it is responsible for up to
half of HIV-related deaths [1,2].
HIV co-infection increases the risk of tuberculosis either by
facilitating reactivation of a remote latent infection (LTBI) or by
favoring the progression of a recently acquired infection towards
active disease. Therefore, rapid identification and early treatment
of active tuberculosis cases in order to interrupt further
transmission, as well as the detection and treatment of LTBI to
prevent progression to active disease, are crucial for controlling
HIV-associated tuberculosis [3]. However, the lack of accuracy of
clinical and radiographic manifestations of tuberculosis in HIV-
infected patients and the limitations of diagnostic tests pose great
obstacles to rapid diagnosis and delay the initiation of specific
treatment [4]. Furthermore, the well-known shortcomings of the
tuberculin skin test (TST) for diagnosing LTBI hamper the
accurate targeting of HIV-infected patients for isoniazid preven-
tive therapy (IPT) [5].
T-cell-based interferon-gamma (IFN-c) release assays (IGRAs)
constitute a promising alternative to TST for diagnosing
tuberculosis infection. IGRAs use highly M. tuberculosis-specific
antigens which are not present in most non-tuberculous myco-
bacteria or in the bacillus Calmette-Gue ´rin vaccine [6]. Two
commercial tests are available: the QuantiFERONH-TB Gold In-
Tube (QFT-GIT) test (Cellestis Ltd, Carnegie, Australia), which
uses ELISA to detect IFN-c in the culture supernatant, and the T-
SPOTH.TB (Oxford Immunotec, Abingdon, UK), which is based
on the enzyme-linked immunospot (ELISpot) assay.
In low-burden tuberculosis settings, IGRAs have shown better
specificity and equal or greater sensitivity than TST for the
detection of tuberculosis infection, and a better correlation with
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advantages have raised great hopes for a better assessment of
tuberculosis infection in people at risk, particularly in immuno-
suppressed and BCG-vaccinated individuals. Although in the
absence of any supporting evidence, IGRAs have also been
increasingly used as diagnostic tests for active tuberculosis. This
practice has raised concern, particularly in high-burden and
resource-limited countries, where the high background LTBI
prevalence and the HIV-associated immunosuppression may limit
their potential value as rule-in or rule-out tests. Based on recently
published meta-analyses showing a suboptimal accuracy for either
diagnosing or predicting subsequent active tuberculosis [10–12],
the World Health Organization (WHO) issued a consensus
statement in which an expert panel advised against the use of
IGRAs for diagnosing active tuberculosis, irrespective of HIV
status, or for identifying people at risk for active tuberculosis
disease in low- and middle-income countries [13]. With regard to
HIV-infected people, the WHO report stressed the very low
quality of evidence for using IGRAs in these patients, and
recommended that these tests should not replace TST for the
assessment of LTBI [13].
Although IGRAs were not developed to replace conventional
microbiological methods for the diagnosis of active tuberculosis
disease, they may have an adjunctive role in symptomatic patients
with suspicion of active disease by complementing clinical-
radiographic and epidemiological data to guide diagnosis work-
up. Therefore, knowing how HIV infection compromises the
IGRAs’ ability to detect tuberculosis infection in patients with
active disease is essential in order to determine their role in
different clinical and epidemiological settings.
We conducted a comprehensive systematic review (SR) to assess
the sensitivity and specificity of IGRAs for the diagnosis of active
tuberculosis disease, their value to predict development of
subsequent active tuberculosis, and the proportion of indetermi-
nate results in HIV-infected adults. Whenever feasible, we assessed
how HIV-associated CD4
+ T-cell depletion affects IGRA
performance, and tried to identify differences according to
tuberculosis burden settings and HIV infection status.
Figure 1. Flowchart for study selection.
doi:10.1371/journal.pone.0032482.g001
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This SR was conducted in accordance with the PRISMA
statement [14]. Ethical approval was not required for this study.
Search
We systematically searched for studies published between 1
January 2005 and 31 July 2011 that evaluated the diagnostic
performance of IGRAs for tuberculosis or LTBI in HIV-positive
adult populations (or populations with at least five HIV-positive
individuals). We searched MEDLINE, the Cochrane Central
Register of Controlled Trials, and the Biomedicine Database
(IME) of the Spanish National Research Council (CSIC). Searches
comprised a combination of the following terms: ‘‘HIV’’,
‘‘immunosuppressed patients’’, ‘‘tuberculosis’’, ‘‘latent tuberculosis
infection’’, ‘‘QuantiFERON’’, ‘‘QuantiFERON-TB Gold’’, ‘‘T-
SPOT.TB’’, ‘‘interferon-gamma release assays’’, and ‘‘T-cell
assays’’, as listed in titles, abstracts or text words. Searches were
limited to studies published in English or Spanish. We also
reviewed citations of the original and review articles, and
guidelines for additional references. When necessary, we contacted
the authors of the studies for additional information.
Selection
For our analysis, we selected only prospective studies that usedthe
commercial tests QuantiFERONH-TB Gold In-Tube and T-
SPOTH.TB performed in blood with 16–24 h of incubation. We
excluded studies of non-commercial IGRAs or studies based on the
old version of the ELISA assay (QuantiFERONH-TB Gold), as well
as studies presenting non-original data, conference abstracts,
editorials, reviews, guidelines, and studies conducted in animals.
Quality assessment
We checked the quality of the studies used to calculate assay
accuracy with the QUADAS check list [15].
In the case of indeterminate results, we appraised the quality of
the studies by assessing whether or not a definition was given in the
methods section (‘‘performed and interpreted according to the
manufacturer’s instructions’’ was acceptable), and whether or not
data for the two types of indeterminate tests (low IFN-c production
in the positive control or high IFN-c production in the negative
control) were reported separately. In addition, since an insufficient
number of peripheral blood mononuclear cells (PBMCs) precludes
performance of the T-SPOT.TB test, we also checked whether or
not these unsuccessful test attempts (failure tests) had been reported.
To evaluate the quality of the studies that assessed the risk of
subsequent tuberculosis according to the result of an IGRA assay,
we used the Newcastle-Ottawa Scale (NOS) for non-randomized
cohort studies [16].
Data extraction
Two researchers (M.S. and L.M.) independently compiled the
data using a standardized data extraction sheet. Discrepancies
Table 1. General and outcome-related characteristics of the 38 studies.
Outcome
Variable Overall Diagnosis of active tuberculosis Development of tuberculosis Indeterminate results
Studies 38 20 3 36
Tuberculosis burden setting
High-burden countries 19 13 – 18
Low/intermediate-burden countries 18 7 3 17
Both* 1 – – 1
Individuals enrolled
Total
-HIV-infected 6514 3155 1166 6434
-HIV-uninfected 3437 1034 135 3437
Median (IQR)
-HIV-infected 90 (160) 98 (138) 266 (362) 107 (166)
-HIV-uninfected 106 (194)** 106 (180) – 105 (178)
Male : female ratio
{ 2.8 : 1 1.5 : 1 2.3 : 1 2.6 : 1
CD4+ counts, cells/mL
{
Median (16 studies), n/N (%)
,200 7/18 (39) 7/8 (88) 2/3 (67) 12/16 (75)
,350 12/18 (67) 7/8 (88) 2/3 (67) 12/16 (75)
Test evaluated
QFT-GIT 17 10 2 17
T-SPOT.TB 11 5 1 17
QFT-GIT & T-SPOT.TB 10 5 0 9
IQR: interquartile range; n/N: number of studies with the condition/total number of studies;
*Switzerland and sub-Saharan area.
**Calculated from 17 studies enrolling HIV-uninfected individuals.
{Data available for 34 studies;
{Only HIV-infected individuals.
doi:10.1371/journal.pone.0032482.t001
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were extracted: year of publication, period and country, number of
participants, gender, test evaluated, CD4
+ cell count, development
of active tuberculosis, TST results, indeterminate test results
(overall and by two CD4
+ cell count thresholds) and fraction of
individuals with true positive, false negative, true negative and
false positive results for the calculation of the test sensitivity and
specificity.
Quantitative data synthesis and analysis
We assessed the following outcomes for each study and pooled
them when feasible: sensitivity and specificity for active tubercu-
losis, predictive value for incident active tuberculosis, and rates of
indeterminate results. The following definitions were used:
sensitivity refers to the proportion of culture-proven tuberculosis
patients who had a positive IGRA test, and specificity refers to the
proportion of symptomatic non-tuberculosis patients who had a
negative IGRA test. For the sensitivity calculation, we included
only patients with confirmed tuberculosis (either with a positive
culture for M. tuberculosis, a positive nucleic acid amplification test,
or characteristic histopathological findings and response to specific
treatment) that was still untreated or had been treated for less than
two weeks. Indeterminate results were included as false negatives.
For the specificity calculation, we selected studies that had enrolled
patients with suspected active tuberculosis (either symptoms
potentially caused by tuberculosis or a clinical and radiographic
picture suggestive of tuberculosis). Results due to low IFN-c
production in the phytohaemagglutinin (PHA)-stimulated well or
high background IFN-c production were defined as indeterminate.
Since T-SPOT.TB tests not performed due to insufficient PBMC
cells are usually excluded from the analyses, we used the term
‘‘failure tests’’ for unrealizable tests. We assessed the effect of
immunosuppression on sensitivity and indeterminate result rates
by pooling and stratifying the results for 200 CD4
+ T-cell count
threshold.
Results are presented for each IGRA assay and for countries
grouped by tuberculosis burden: high-burden (.40 cases per
100,000 population), low- to intermediate-burden (,40 cases per
100,000 population) [17]. Head-to-head comparisons between
HIV-infected and HIV-uninfected individuals, as well as between
the two IGRA assays and TST, were performed whenever possible.
We calculated combined estimates of pooled sensitivity,
specificity and the 95% confidence interval (CI). The pooled
effect for binary outcomes was presented as the difference with the
95% CI. A random-effects synthesis model meta-analysis was used
to pool the effect across the studies. Inconsistency was quantified
by the I
2 statistic. Forest plots were constructed to show the effect
size of all the studies and the variability of the pooled estimates.
The analyses were performed with MetaAnalyst software [18].
Results
Characteristics of the studies
Of the total of 677 citations identified, 38 were eligible for
analysis (Figure 1) [19–56]. The studies included were conducted
in 17 different countries, 19 (50%) in high-burden countries, 18
(47.4%) in low-burden tuberculosis countries, and one (2.6%)
included participants from both settings. Thirty-seven were
published in English and one in Spanish. Some industry
involvement was reported in 11 studies (28.9%), mainly in the
form of donation of IGRA kits to the researchers. Of the 20 studies
used to calculate sensitivity/specificity, 13 (65%) corresponded to
high-burden countries. A summary of the 38 studies included is
provided in Table 1. Detailed information on the studies included
in the review is available upon request.
Quality of the studies
Eight of the 20 studies (40%) used to calculate sensitivity and
specificity met all the quality indicators, ten (50%) met between
75% and 100%, and two (10%) met less than 75%.
Indeterminate results due to high production of IFN-c in the
negative control were either not defined as such or excluded from
the analysis in 32% of studies with QFT-GIT and in 28% with T-
SPOT.TB. The results for the two types of indeterminate results
were reported separately in 27% of studies with QFT-GIT and in
32% with T-SPOT.TB. Only three studies (16%) provided data
on the T-SPOT.TB tests not performed because of insufficient
quantities of cells.
As for the studies evaluating the ability of IGRAs to predict
subsequent tuberculosis, follow-up was adequate in all three (12,
19 and 20 months respectively), and the exposed sample was
representative of the HIV population; however, there was no
adequate outcome assessment (pre-test and during follow-up) in
any of them, and the number of incident tuberculosis cases was
low (zero, two and three cases respectively). More detailed
information on the quality of the studies is available upon request.
Figure 2. Sensitivity of QuantiFERON-TB Gold In-Tube (A) and T.SPOT.TB (B), in HIV-infected patients with confirmed tuberculosis, stratified for
tuberculosis burden setting. Pooled estimates derived from random effects (DerSimonian-Laird) modeling.
doi:10.1371/journal.pone.0032482.g002
Table 2. Head-to-head comparison of sensitivity between QFT-GIT and T-SPOT.TB in HIV-infected patients with culture-confirmed
tuberculosis.
Reference Country Sensitivity QFT-GIT Sensitivity T-SPOT.TB Sensitivity difference
n/N (%) n/N (%) QFT-GIT (%) – T-SPOT.TB (%)
Chee et al. [20] Singapore 4/7 (57) 7/7 (100) 243
Markova et al. [21] Bulgaria 12/13 (92) 8/13 (62) 30
Leidl et al. [24] Uganda 13/19 (68) 17/19 (89) 221
Ling et al. [31] South Africa 29/43 (67) 35/43 (81) 214
Dheda et al. [33] South Africa 1/5 (20) 5/5 (100) 280
QFT-GIT: QuantiFERONH-TB Gold In-Tube; n/N: positive cases/cases with active tuberculosis.
doi:10.1371/journal.pone.0032482.t002
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Sensitivity. The sensitivity of QFT-GIT was estimated from
15 studies with a total of 356 participants with culture-proven
active tuberculosis [19–33], and the sensitivity of T-SPOT.TB was
estimated from nine studies with 311 participants with culture-
proven active tuberculosis [20,21,24,31,33–37]. The pooled
sensitivity was 61% (95% CI 54–67; I
2=46.6%) for QFT-GIT
and 65% (95% CI 56–74; I
2=67.5%) for T-SPOT.TB (Figure 2).
Five studies compared the sensitivity of QFT-GIT and T-
SPOT.TB head to head [20,21,24,31,33]. The pooled sensitivity
was 69% (95% CI 57–79; I
2=35.9) for QFT-GIT and 79% (95%
CI 65–88; I
2=66.4) for T-SPOT.TB. The results of simultaneous
TST and QFT-GIT in patients with active tuberculosis were
reported in five studies [19,22,23,25,32]. The pooled sensitivity
was 67% (95% CI 58–74; I
2=0.0%) for QFT-GIT and 60%
(95% CI 34–82; I
2=46.2%) for TST. T-SPOT.TB was
compared with TST in one study with 13 patients [38]: excluding
the indeterminate results, the sensitivities were 85% and 46% for
T-SPOT.TB and TST respectively. Tables 2 and 3 show the
differences in sensitivity between QFT-GIT and T-SPOT.TB,
and between IGRAs and TST respectively in HIV-infected
patients.
Six studies, covering 634 participants with tuberculosis (113
HIV-infected and 521 HIV-uninfected) evaluated the sensitivity of
QFT-GIT according to HIV status [19,20,25,29,31,33]. The
pooled sensitivity was 65% (95% CI 55–74; I
2=9.8%) and 79%
(95% CI 75–83; I
2=24.9%) in HIV-infected and HIV-uninfected
patients respectively. As for T-SPOT.TB, three studies compared
sensitivity between HIV-infected and uninfected patients (55 HIV-
infected and 364 HIV-uninfected) [20,31,33]. The pooled
sensitivity was 75% (95% CI 64–84; I
2=39.1%) in HIV-infected
and 90% (95% CI 84–94; I
2=74%) in HIV-uninfected patients.
Table 4 shows the differences in sensitivity of the two IGRA assays
according to HIV status.
The effect of CD4
+ cell counts on sensitivity was evaluated in
three studies with QFT-GIT [23,28,31] and three studies with T-
SPOT.TB [31,34,37]. While one study on QFT-GIT reported a
decrease in its sensitivity with fewer than 200 circulating CD4
+
cells [23], another found no differences in CD4
+ T-cell counts
between patients with positive and negative results [28]. A third
Table 4. Comparison of sensitivity of IGRAs between HIV-infected and HIV-uninfected patients with culture-confirmed
tuberculosis.
Reference Country Sensitivity in HIV-pos Sensitivity in HIV-neg Sensitivity difference
n/N (%) n/N (%) HIV-pos (%) – HIV-neg (%)
QFT-GIT
Tsiouris et al. [19] South Africa 17/26 (65) 11/15 (73) 28
Chee et al. [20] Singapore 4/7 (57) 220/273 (81) 224
Garcia-Gasalla et al. [25] Spain 12/13 (92) 85/105 (81) 11
Legesse et al. [29] Ethiopia 13/19 (68) 20/31 (65) 3
Ling et al. [31] South Africa 29/43 (67) 67/82 (82) 215
Dheda et al. [33] South Africa 1/5 (20) 11/15 (73) 253
T-SPOT.TB
Chee et al. [20] Singapore 7/7 (100) 247/267 (93) 7
Ling et al. [31] South Africa 35/43 (81) 70/82 (85) 24
Dheda et al. [33] South Africa 5/5 (100) 14/15 (93) 7
IGRAs: Interferon-c release assays; QFT-GIT: QuantiFERONH-TB Gold In-Tube; n/N: positive cases/cases with active tuberculosis.
doi:10.1371/journal.pone.0032482.t004
Table 3. Head-to-head comparison of sensitivity between IGRAs and TST in HIV-infected patients with culture-confirmed
tuberculosis.
Reference Country IGRA Sensitivity IGRA Sensitivity TST Sensitivity difference
n/N (%) n/N (%) IGRA (%) – TST(%)
Tsiouris et al. [19] South Africa QFT-GIT 17/26 (65) 22 (85) 220
Aichelburg et al. [22] Austria QFT-GIT 10/11 (91) 8 (80)* 11
Kabeer et al. [23] India QFT-GIT 29/44 (66) 11 (25) 41
Garcia-Gasalla et al. [25] Spain QFT-GIT 9/13 (69) 5 (42)** 27
Rangaka et al. [32] South Africa QFT-GIT 32/50 (64) 34 (68) 24
Vincenti et al. [38] Italy T-SPOT.TB 11/13 (85) 6 (46){ 39
IGRAs: Interferon-c release assays; QFT-GIT: QuantiFERONH-TB Gold In-Tube; TST: Tuberculin skin test; n/N: positive cases/cases with active tuberculosis.
*8 positive tests of 10 cases;
**5 positive tests of 12 cases;
{Indeterminate results of T-SPOT.TB excluded.
doi:10.1371/journal.pone.0032482.t003
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doi:10.1371/journal.pone.0032482.g003
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+ cells
(76%; 95% CI 53–92) than in those with $200 CD4
+ cells (61%;
95% CI 36–83) [31]. None of the three studies assessing T-
SPOT.TB reported a relationship between lower sensitivity and
lower CD4
+ T-cell counts [31,34,37]. In fact, as in the case of
QFT-GIT, the sensitivity of T-SPOT.TB in one study was higher
in patients with CD4
+ cells ,200 (90%; 95% CI 67–99) than in
those with CD4
+ cells $200 cells (78%; 95% CI 52–94) [31].
Specificity. The specificity of QFT-GIT was calculated from
eight studies covering a total of 1334 participants without active
tuberculosis [21,23,26,27,29–32], whilst that of T-SPOT.TB was
calculated from six studies with a total of 326 participants without
active tuberculosis [21,31,34–36,38]. The pooled specificity was
72% (95% CI 56–84; I
2=93.2%) for QFT-GIT, and 70% (95%
CI 55–83; I
2=87.8%) for T-SPOT.TB (Figure 3).
Predictive value of IGRAs for incident active tuberculosis
Three longitudinal studies assessed incident active tuberculosis
[22,43,52]; all of them were conducted in low-burden countries.
In a prospective cohort study, 830 HIV-infected patients who
underwent QFT-GIT testing were left untreated and were
followed periodically [22]. Of 822 individuals without active
tuberculosis at baseline, 36 were positive. After a median follow-
up of 19 months, three (8.3%) patients with positive QFT-GIT
developed tuberculosis, but none of the 705 patients with a
negative QFT-GIT developed active disease. In another study
with 201 HIV-seropositive individuals, two out of 20 infected
patients with positive T-SPOT.TB who did not receive
preventive treatment developed active tuberculosis during the
first year [52]. In a third study assessing 135 HIV-infected
individuals, none of the 103 patients who had a negative or
indeterminate QFT-GIT result and negative TST at baseline
developed tuberculosis after a median follow-up of 20 months
[43] (Table 5).
Indeterminate IGRA results
Twenty-six studies reported data on indeterminate results in
patients tested with QFT-GIT, with a total of 5209 participants
[19–33,39–49]. The pooled indeterminate rate was 8.2% (95% CI
6.0–11.2; I
2=46.8%) (Figure 4A). When the analysis was
restricted to the seven studies that differentiated the two types of
indeterminate results, 11 out of 120 (9.2%) indeterminate results
were due to high background IFN-c production (negative control),
and the other 109 (90.8%) were due to low IFN-c production in
the positive control.
Eighteen studies including a total of 2236 participants reported
data on indeterminate results with T-SPOT.TB [20,21,24,31–
34,36,37,41,46,47,50–56]. The pooled indeterminate rate was
5.9% (95% CI 3.5–9.8; I
2=47.0%) (Figure 4B). When the analysis
was restricted to the three studies that provided data on failure
tests (not performed due to an insufficient number of PBMCs), the
pooled indeterminate rate was 20.6% (95% CI 11.1–34.9;
I
2=48.3%). Of the 153 indeterminate results derived from these
three studies, 51 (33.3%) were due to failure to perform the test, 50
(32.7%) were due to low IFN-c production in the PHA-stimulated
well, and 52 (34%) to high background IFN-c production.
In eight studies that compared QFT-GIT and T-SPOT.TB
head to head [20,21,24,31,33,41,46,47]. Pooled proportion were
5.7% (95% CI 2.1–14.7; I
2=46.9%) for QFT-GIT, and 6.1%
(95% CI 3.2–11.2; I
2=40.5%) for T-SPOT.TB (Table 6).
The pooled indeterminate rates for high-burden countries were
12.0% (95% CI 8.6–16.4; I
2=44.5%) for QFT-GIT and 7.7%
(95% CI 3.6–15.5; I
2=47.6%) for T-SPOT.TB. Pooled indeter-
minate rates in low/intermediate-burden countries were 6.4%
(95% CI 1.1–12.9; I
2=47.6%) for QFT-GIT and 3.5% (95% CI
1.4–8.4; I
2=44.8%) for T-SPOT.TB. When stratified for type of
patients (patients evaluated because of suspicion of tuberculosis,
patients with culture-confirmed tuberculosis and patients screened
for LTBI), pooled indeterminate rates for QFT-GIT were higher
for patients with active tuberculosis (15.3%; 95% CI 10.8–21.2;
I
2=17.1%) and for symptomatic patients (12.3%; 95% CI 6.9–
39.4; I
2=48.4%) than for those screened for LTBI (3.9%; 95% CI
2.4–6.4; I
2=45.3%). Pooled indeterminate rates for T-SPOT.TB
were higher for symptomatic patients (9.1%; 95% CI 4.0–19.3;
I
2=48.2%) than for those screened for LTBI (4.3%; 95% CI 2.2–
8.1; I
2=42.9%).
Eleven studies allowed a comparison of rates of indeterminate
results between HIV-infected and HIV-uninfected individuals
[19,20,24,29,31,33,42,43,45,50,53]. Indeterminate rates were
higher in HIV-infected than in HIV-uninfected individuals for
the QFT-GIT test, but the difference did not reach statistical
significance (difference 4.6%; 95% CI -1 to 10; I
2=58.8%), as was
the case of T-SPOT.TB (difference 0.7%; 95% CI -2 to 3;
I
2=0.0%) (Figure 5).
Effect of CD4
+ cell counts on indeterminate
results. Indeterminate result rates according to 200 CD4+ T-
cell count threshold could be pooled from seven studies with QFT-
GIT [21,22,39,41–44] and six with T-SPOT.TB [21,34,36,41,
50,51]. The pooled indeterminate rates were 11.6% (95% CI 7.0–
18.6; I
2=34.7%) for CD4+,200, and 3.1% (95% CI 1.1–8.5;
Table 5. Risk of active tuberculosis according to IGRA result in patients not receiving preventive treatment.
Reference Country IGRA No. of individuals Median follow-up
Cumulative
incidence Risk difference IGRA-pos - IGRA-neg
Median follow-up Cases (%; 95%CI) IGRA-pos - IGRA-neg % (95%CI)
Clark et al. [52] U. Kingdom T-SPOT.B 20 T-SPOT.TB-pos 12 months 2 (10%; 1.8–33.0) 10% (23t o2 3 )
114 T-SPOT.TB-neg 3 months 0 (0%; 0.0–3.0) 10% (23t o2 3 )
Aichelburg et al. [22] Austria QFT-GIT 36 QFT-GIT-pos 19 months 3 (8.3%; 1.8–22.0) 8.3% (20.7 to 17)
705 QFT-GIT-neg 0 (0%; 0.0–0.5)
44 QFT-GIT Ind 0 (0%; 0.0–9.0)
Santin et al. [43] Spain QFT-GIT 101 QFT-GIT-neg 20 months 0 (0%; 0.0–4.5) N.A.
2 QFT-GIT Ind
QFT-GIT=QuantiFERONH-TB Gold In-tube; Ind.=indeterminate; N.A.=not applicable.
doi:10.1371/journal.pone.0032482.t005
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2=47.4%) for CD4+ $200 (difference 8.1%; 95% CI 2.6–13.7;
I
2=59.8%) for QFT-GIT, and 11.4% (95% CI 5.1–23.8;
I
2=43.1%) for CD4+,200, and 7.9% (95% CI 4.6–13.3;
I
2=24.6%) for CD4+$200 (difference 4.0%; 95% CI -0.5 to
8.5; I
2=0.0%) for T-SPOT.TB (Figure 6).
Discussion
This SR provides a comprehensive summary of the current
evidence on the performance of the two commercial IFN-c-based
assays for the immunodiagnosis of tuberculosis and tuberculosis
infection in HIV-infected adults. The main results can be
summarized as follows. First, the sensitivity and specificity of either
IGRA in HIV-infected people is suboptimal for being used alone to
rule in or rule out active tuberculosis disease. Second, the risk of
tuberculosis in the short- to medium-term in HIV-infected adults
with a negative QFT-GIT seems to be low. Third, indeterminate
results of IGRAs were more frequent in HIV-infected patients with
active tuberculosis from high-burden tuberculosis countries. Fourth,
HIV-associated immunosuppression, measured by circulating
CD4
+ T-lymphocytes, negatively affects the performance of QFT-
GIT, and to a lesser extent, T-SPOT.TB.
The sensitivity of IGRAs for culture-confirmed tuberculosis in
the current SR was lower than that reported in three meta-
analyses including predominantly immunocompetent people
[8,9,11], and similar to that reported for HIV-infected patients
in the three previous SRs [10,11,12]. Taken together, the results of
the previous SRs and our own show that the sensitivity of QFT-
GIT is roughly 65%, ranging between 61% reported by
Cattamanchi et al. [10] in low-income countries and 68%
reported by Chen et al. [12] in both high and low-income
countries. For T-SPOT.TB, the sensitivity was close to 70%,
ranging between 65% obtained in the current SR and 72%
reported by Cattamanchi et al. [10] in low-income countries.
These figures mean that, at best, IGRAs will miss one in three
cases of active tuberculosis (Table 7).
HIV-associated immunosuppression, measured by circulating
CD4
+ T-cells, weakens the ability of IGRAs to detect tuberculosis
infection. A previous SR [10] explored the impact of immuno-
suppression on the proportion of positive results according to a
200 CD4
+ T-cell threshold, regardless of whether they had active
tuberculosis or not. However, the value of the information
provided by this approach is limited because the analysis included
healthy people with unknown LTBI status. In the current SR, we
tried to determine the impact of CD4
+ T-cell counts on the
sensitivity of IGRAs in HIV-infected patients with active
tuberculosis disease, but the results were inconclusive. While
one of the three studies with QFT-GIT [23,28,31] observed
lower sensitivity with CD4
+ below 200 cells/mm
3 [23], another
one found higher sensitivity with CD4
+ below 200 cells/mm
3
[31], and a third one did not find significant differences in CD4
+
T-cell counts between patients with either positive or negative
QFT-GIT [28]. As for T-SPOT.TB, while two of the three
studies [31,34,37] found no change in sensitivity with CD4+ T-
cell counts [34,37], the other one found higher sensitivity in
patients with CD4
+ below 200 cells/mm
3 [31]. Since the decrease
in sensitivity of IGRAs in HIV-infected patients is largely due to
high rates of indeterminate results, the correct reporting of these
results is essential for an accurate assessment of the sensitivity of
the IGRA tests. Unfortunately, indeterminate results due either to
a high-background production of interferon-c (negative control)
or to a failure test due to an insufficient number of PBMCs are
often explicitly excluded or not reported. In fact, in the three
studies that provided these data, a third of all invalid T-
SPOT.TB results were due to failed T-SPOT.TB tests because of
a lack of cells [36,37,47]. This may lead to an overestimation of
the sensitivity of T-SPOT.TB assay in HIV-infected patients, and
challenges the commonly held assumption that performance of T-
SPOT.TB is less affected (if at all) by CD4
+ T-cell depletion than
QFT-GIT.
It has been suggested that IGRAs are less affected than TST by
HIV-associated immunosuppression. However, there is no consis-
tent evidence that the IGRAs are more sensitive for detecting
tuberculosis infection in patients with active disease. Data from the
five studies reporting comparisons between QFT-GIT and TST
yielded a pooled sensitivity of 67% and 60% respectively. Actually,
Figure 4. Proportion of indeterminate results of QuantiFERON-TB Gold In-Tube (A) and T-SPOT.TB (B) in HIV-infected patients, stratified for
tuberculosis burden setting. Pooled estimates derived from random effects (DerSimonian-Laird) modeling.
doi:10.1371/journal.pone.0032482.g004
Table 6. Head-to-head comparison of the proportion of indeterminate results between QFT-GIT and T-SPOT.TB in HIV-infected
patients.
Reference Country Population tested
Indeterminate results QFT-
GIT
Indeterminate results T-
SPOT.TB
Difference indeterminate
results
n/N (%) n/N (%) QFT-GIT(%) - T-SPOT.TB (%)
Chee et al. [20] Singapore Active TB 0/7 0/7 –
Markova et al. [21] Bulgaria Symptomatic ptes 5/90 (5.6) 11/90 (12.2) 26.6
Leidl et al. [24] Uganda Screened for LTBI 4/128 (3.1) 6/128 (4.7) 21.6
Ling et al. [31] South Africa Symptomatic ptes 27/108 (25.0) 2/108 (2.0) 23.0
Dheda et al. [33] South Africa Symptomatic ptes 8/20 (40.0) 1/20 (5.0) 35.0
Latorre et al. [41] Spain Screened for LTBI 1/75 (1.3) 1/75 (1.3) 0
Dominguez et al. [46] Spain Screened for LTBI 0/19 0/19 –
Talati et al. [47] USA Screened for LTBI 6/336 (1.8) 47/336 (13.9) 212.1
IGRAs: Interferon-c release assays; QFT-GIT: QuantiFERONH-TB Gold In-Tube; n/N: indeterminate results/individuals tested; TB: tuberculosis; LTBI: latent tuberculosis
infection; ptes: patients.
doi:10.1371/journal.pone.0032482.t006
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was at least as sensitive as QFT-GIT [32].
As might be expected, the specificity of either IGRA for active
tuberculosis disease was suboptimal for use as a rule-in test [9].
Although IGRAs use highly M. tuberculosis-specific antigens, since
they do not distinguish between latent and active infection they
cannot provide optimal specificity. Besides, they reflect the high
prevalence of LTBI in the countries in which most of the studies
were conducted [57]. Whether the specificity of IGRAs in low-
burden tuberculosis settings is better is currently unclear. The
present SR identified only three studies in low-burden settings, all
from Italy: two with QFT-GIT [26,27] and one with T-SPOT.TB
[38]. Specificity was 89% for QFT-GIT in both studies, and 64%
for T-SPOT.TB (Table 7).
Although culture-confirmed tuberculosis has been commonly
used as a surrogate for tuberculosis infection, tuberculosis-
associated immunodeficiency may impair the ability of IGRAs to
detect the infection, particularly in HIV-infected patients.
Therefore, their actual sensitivity for LTBI may be underestimated
by extrapolating from patients with active disease [58]. Deter-
mining the capability of IGRAs to predict the risk of subsequent
active tuberculosis is another way of evaluating the IGRAs
suitability for detecting LTBI. A comprehensive SR, including
mainly studies with non-HIV-infected individuals, showed a
marginal advantage of IGRAs over the TST for predicting
incident active tuberculosis [59]. Two studies identified in the
current SR, both conducted in low-burden tuberculosis countries,
showed modest associations between positive IGRA result and
incident active tuberculosis in the short- to medium term [22,52].
Conversely, a negative result of QFT-GIT had a high negative
predictive value (100%) in two studies [22,43]. These data, if
further confirmed in large, longitudinal and properly designed
studies, would help to improve the targeting of at-risk patients by
reducing the number of people considered for preventive
treatment.
Indeterminate results, due either to low IFN-c production in the
positive control or to high IFN-c production in the negative
control, may negatively affect the overall utility of IGRAs. The
proportion of indeterminate results in the current SR showed huge
differences across studies, ranging from no indeterminate results at
all to rates as high as 25% and 33% for QFT-GIT and T-
SPOT.TB respectively [31,36]. These differences are related to
host characteristics (CD4
+ cell counts), type of evaluated people
(patients with active tuberculosis vs. people evaluated for LTBI),
and setting (high-burden and resource-limited vs. low-burden and
high-income settings), but are also due to differences in the criteria
Figure 5. Comparison of the proportion of indeterminate results between HIV-infected and HIV-uninfected individuals. Pooled
estimates derived from random effects (DerSimonian-Laird) modeling.
doi:10.1371/journal.pone.0032482.g005
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background IFN-c production, as well as failure T-SPOT.TB
tests due to an insufficient number of PBMCs, are often not
counted as such and are excluded from the analyses. Therefore,
the calculation of indeterminate result rates and their association
with potentially influencing factors will inevitably be compromised
by these limitations. Interestingly, the types of indeterminate
results were not equally distributed for the two assays. While low
IFN-c production upon stimulation with PHA (positive control)
accounted for more than 90% of the indeterminate results with the
QFT-GIT assay, half of the indeterminate T-SPOT.TB assays
were due to high-background IFN-c production (negative control).
The pooled indeterminate rates for the two assays were higher
in high-burden settings than in low-burden settings. They were
also higher in patients with symptoms suggestive of tuberculosis or
culture-confirmed tuberculosis than in those screened for LTBI.
Because studies that enrolled patients with active tuberculosis were
mainly carried out in high-burden countries, whilst those that
enrolled patients screened for LTBI were from low-burden
countries, further analyses to determine which of the two factors
has a greater influence on the occurrence of indeterminate results
cannot be performed. On the one hand, HIV-infected patients
usually have profound CD4
+ T-lymphocyte depletion either as a
cause or as a consequence of the disease, which may cause anergy
and indeterminate IGRA results [58]. On the other hand,
indeterminate results have been related to operational factors
mainly linked to resource-limited settings, such as delayed
incubation [60–62], and the location of the laboratory at which
the samples are processed (according to data from Zambia; K.
Shanaube, personal communication) (Table 8).
Our SR has limitations. First, the validity of the results is limited
by the inconsistency across the studies. This heterogeneity
persisted after performing subgroup analyses. Second, the main
body of literature on active tuberculosis comes from high-burden
tuberculosis and resource-limited settings, which limits the
generalization of our estimates. Conversely, studies for the
prediction of subsequent development of active disease in HIV-
infected patients were exclusively from low-burden countries.
Therefore, the low risk of subsequent active tuberculosis for
patients testing negative on QFT-GIT obtained in two low-burden
countries in Europe cannot be extrapolated to countries with high
burdens of tuberculosis such as Sub-Saharan African countries.
Finally, the lack of an adequate standard for latent tuberculosis
infection is a inherent limitation to every SR to draw confident
Figure 6. Differences in the proportion of indeterminate results of IGRAs by 200 CD4
+ cell count threshold. Pooled estimates derived
from random effects (DerSimonian-Laird) modeling.
doi:10.1371/journal.pone.0032482.g006
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infection in people without evidence of active disease.
Nonetheless, some relevant conclusions may be drawn from this
SR. First, the current evidence indicates that neither IGRA is able
to replace conventional microbiological diagnosis of tuberculosis in
HIV-infected patients. Second, QFT-GIT, if the low risk of
subsequent active tuberculosis in HIV-infected patients testing
negative is confirmed, could replace TST for targeting at-risk
patients for chemoprophylaxis in low-burden tuberculosis coun-
tries. Third, potential causes of invalid tests, such as delayed
incubation and other operational factors, should be addressed in
order to improve the performance of IGRAs, particularly in
resource-limited high-burden tuberculosis countries with high
HIV-coinfection prevalence.
Acknowledgments
We thank the Audiovisuals Department of the Bellvitge University Hospital
for the assistance with graphics.
Author Contributions
Conceived and designed the experiments: MS. Analyzed the data: MS LM
DR. Wrote the paper: MS.
Table 7. Sensitivity and specificity of the IGRAs in HIV-
infected patients in four systematic reviews.
Cattamanchi Metcalfe Chen
(Ref. [10]) (Ref. [11]) (Ref. [12]) Current SR
Sensitivity*
High-burden
TB settings
-QFT-GIT 61%
(47–75)
65%
(52–77)
N.D. 61%
(53–69)
-T-SPOT.TB 72%
(62–81)
68%
(56–80)
N.D. 65%
(54–74)
Low-burden
TB settings
-QFT-GIT 67%
(47–83){
N.D. N.D. 59%
(46–71)
-T-SPOT.TB 94%
(73–100){
N.D. N.D. 69%
(47–99){
Overall
-QFT-GIT N.D. N.D. 69%
(62–71)
61%
(54–67)
-T-SPOT N.D. N.D. 66%
(60–71)
65%
(56–74)
Specificity
High-burden
TB settings
-QFT-GIT N.D. 50%
(35–65)
57%
(54–60)
62%
(49–74)
-T-SPOT.TB N.D. 52%
(40–63)
63%
(58–68)
73%
(54–85)
Low-burden
TB settings
-QFT-GIT N.D. N.D. 94%
(93–96)
89%{
-T-SPOT.TB N.D. N.D. 64%
(44–81){
64%
(44–81){
Overall
-QFT-GIT
-T-SPOT.TB N.D. N.D. 63%
(58–68)
70%
(55–83)
NOTE: Stratification for high-burden and low-burden TB settings is roughly
equivalent to low-income and high-income settings used by Cattamanchi [10],
Metcalfe [11] and Chen [12] in their systematic reviews; TB=tuberculosis; QFT-
GIT=QuantiFERON GoldH In-Tube; N.D.=Not done.
*Sensitivity estimated by scoring indeterminate results negative;
{Only one study;
{Two studies: 89% each respectively.
doi:10.1371/journal.pone.0032482.t007
Table 8. Proportion of indeterminate results of IGRAs in HIV-
infected patients in four systematic reviews.
Cattamanchi Metcalfe Chen
(Ref.
[10])
(Ref.
[11])
(Ref.
[12])
Current
SR
Setting
High-burden TB
-QFT-GIT 4%
(1–9)*
15%
(9–21){
11.4%
(9.7–13.2){
12.0%
(8.6–16.4)
-T-SPOT.TB 2%
(0–3)*
9%
(0–17){
14%
(11.4–17.1){
7.7%
(3.6–15.5)
Low-burden TB
-QFT-GIT 4%
(3–6)*
N.D. 8.4%
(6.8–10.2){
6.4%
(1.1–12.9)
-T-SPOT.TB 5%
(1–9)*
N.D. 0%
(0–0.9){
3.5%
(1.4–8.4)
Population
evaluated
Active TB
-QFT-GIT N.D. N.D. N.D. 15.3%
(10.8–21.2)
-T-SPOT.TB N.D. N.D. N.D. 9.1%
(4.0–19.3)
Screened for LTBI
-QFT-GIT N.D. N.D. N.D. 3.9%
(2.4–6.4)
-T-SPOT.TB N.D. N.D. N.D. 4.3%
(2.2–8.1)
Difference by
200 CD4+ count
threshold
-QFT-GIT N.D. N.D. N.D. 8.1%
(2.6–13.7)
-T-SPOT.TB N.D. N.D. N.D. 4.0%
(20.5 to
8.5)
Overall
-QFT-GIT N.D. N.D. 10.0%
(8.8–11.3)
8.2%
(6.0–11.2)
-T-SPOT.TB N.D. N.D. 13.2%
(10.6–16.0)
5.9%
(3.5–9.8)
NOTE: Stratification for high-burden and low-burden TB settings is roughly
equivalent to low-income and high-income settings used by Cattamanchi [10],
Metcalfe [11] and Chen [12] in their systematic reviews; TB=tuberculosis;
LTBI=latent tuberculosis infection; QFT-GIT=QuantiFERON GoldH In-Tube;
N.D.=Not done.
*Only patients screened for LTBI included;
{Symptomatic patients, with and without active TB.
doi:10.1371/journal.pone.0032482.t008
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